USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
SENTIEN BIOTECHNOLOGIES, INC.
Address:
196 Boston Ave
Medford, MA 02155
Phone:
N/A
URL:
N/A
EIN:
263782670
DUNS:
828970900
Number of Employees:
4
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,314,291.00 4
SBIR Phase II $773,285.00 1

Award List:

A Mesenchymal Stem Cell Bioreactor for the Active Treatment of Acute Renal Failur

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$565,011.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The overall goal of this Phase I project is to create technical protocols for the reproducible operation of our proprietary cell-based device for the treatment of acute renal failure. The project specific aims are: (1) To identify active therapeutic secreted… More

SBIR Phase I:Assembly and Storage of Cell-Derived Drug Delivery Devices

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$150,000.00
Agency:
NSF
Principal Investigator:
Abstract:
This Small Business Innovation Research (SBIR) Phase I project proposes the development of a stem cell-based extracorporeal device that can offer unparalleled support to 200,000+ patients undergoing severe acute kidney injury annually. The device delivers cell-derived secretions of anti-inflammatory… More

Mesenchymal Stem Cell Bioreactor for the Active Treatment of Acute Renal Failure

Award Year / Program / Phase:
2012 / SBIR / Phase II
Award Amount:
$773,285.00
Agency:
HHS
Principal Investigator:
Arno W. Tilles – 617-724-2953
Abstract:
DESCRIPTION (provided by applicant): The overall goal of this project is to design a clinical protocol for the operation and monitoring of a mesenchymal stem cell (MSC)-coated dialysis device for the treatment of acute renal failure (ARF) in dogs. The project specific aims are: (1) Biomarker-guided… More

Blood Purification for Organ Failure

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$99,974.00
Agency:
DOD
Principal Investigator:
Arno Tilles, Chief Technology Officer – (781) 361-9031
Abstract:
Sentien Biotechnologies is developing cellular devices for the treatment of acute organ failure, including polytrauma-induced multiple organ dysfunction syndrome (MODS). Our flagship product, the Sentinel, is a dialyzer with mesenchymal stem cells (MSCs) seeded in the extracapillary space, designed… More

Cellular Device for the Treatment of Acute Liver Failure

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$499,306.00
Agency:
HHS
Principal Investigator:
Arno W. Tilles – 617-724-2953
Abstract:
DESCRIPTION (provided by applicant): The goal of this Phase I project is to develop a cell-coated device for the treatment of acute liver failure. The device harnesses mesenchymal stem cell secretions to provide combined anti-inflammatory and regenerativesupport. The project specific aims are: (1)… More